Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the αvβ3 integrin and PI3-K/Akt signaling

International Journal of Oncology

Volumn 28, Issue 3, 2006, Pages 723-730

  Marelli, Marina Montagnani ^a   Moretti, Roberta M ^a   Procacci, Patrizia ^a   Motta, Marcella ^a   Limonta, Patrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cell motility; IGF I; Integrins; PI3 K Akt; Prostate cancer

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ACTIN; ANDROGEN; ANTIBODY; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MORPHOLINE DERIVATIVE; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VITRONECTIN RECEPTOR;

ARTICLE; CELL MOTION; CYTOSKELETON; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PSEUDOPODIUM; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ULTRASTRUCTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTINS; ANDROGENS; ANTIBODIES; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; CHROMONES; CYTOSKELETON; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTEGRIN ALPHAVBETA3; MALE; MICROSCOPY, ELECTRON, SCANNING; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NITRILES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PSEUDOPODIA; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 33645224456     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Miyamoto H, Messing EM and Chang C: Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61: 332-353, 2004.
3. Lee ECY and Tenniswood MPR: Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy. J Cell Biochem 91: 662-670, 2004.
4. Arnold JT and Isaacs JT: Mechanisms involved in the progression of androgen-independent prostate cancers: it is only the cancer cell's fault. Endocr-Rel Cancer 9: 61-73, 2002.
5. Navarro D, Luzardo OP, Fernandez L, Chesa N and Diaz-Chico BN: Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81: 191-201, 2002.
6. Martel CL, Gumerlock PH, Meyers FJ and Lara PN: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29: 171-187, 2003.
7. Assikis VJ and Simons JW: Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin Oncol 31: 26-32, 2004.
8. Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518, 2004.
9. Djavan B, Waldert M, Seitz C and Marberger M: Insulin-like growth factors and prostate cancer. World J Urol 19: 223-225, 2001.
10. Iwamura M, Sluss PM, Casamento JB and Cockett ATK: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252, 1993. (Pubitemid 23184735)
11. Connolly JM and Rose DP: Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24: 167-175, 1994.
12. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M and Fujita-Yamaguchi Y: Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines: LNCaP, DU145 and PC-3 cells. Int J Urol 3: 39-46, 1996.
13. Montagnani Marelli M, Moretti RM, Dondi D, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140: 329-334, 1999.
14. Burfeind P, Chernicky CL, Rininsland F and Ilan J: Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93: 7263-7268, 1996.
15. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME and Cox ME: Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64: 8620-8629, 2004.
16. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61: 6276-6280, 2001.
17. Kaplan PJ, Mohan S, Cohen P, Foster BA and Greenberg NM: The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59: 2203-2209, 1999.
18. Chan JM, Stampfer MK, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH and Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998.
19. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G and Kaaks R: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910-1917, 2000.
20. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF and Macaulay VM: Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62: 2942-2950, 2002.
21. Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 21: 91-100, 2002.
22. Zheng D-Q, Woorward AS, Fornaro M, Tallini G and Languino LR: Prostatic carcinoma cell migration via αvβ3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59: 1655-1664, 1999.
23. Moretti RM, Montagnani Marelli M, Motta M and Limonta P: Role of the orphan nuclear receptor RORα in the control of the metastatic behavior of androgen-independent prostate cancer cells. Oncol Rep 9: 1139-1143, 2002.
24. Grimberg A: Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2: 630-635, 2003.
25. Klein RD and Fischer SM: Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and DU145 prostate carcinoma cells. Carcinogenesis 23: 217-221, 2002.
26. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F and Klocker H: Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I and protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59: 227-233, 1999.
27. Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC and Languino LR: Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 161: 817-826, 2003.
28. Grzmil M, Hemmerlein B, Thelen P, Schweyer S and Burfeind P: Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3 and suppresses MMP-2 expression. J Pathol 202: 50-59, 2004.
29. Zhang H and Yee D: The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Exp Opin Invest Drugs 13: 1569-1577, 2004.
30. Jackson JG, Zhang X, Yoneda Y and Yee D: Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 20: 7318-7325, 2001.
31. Guvakova MA, Adams JC and Boettiger D: Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci 115: 4149-4165, 2002.
32. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion and metastasis of breast cancer. Cancer Res 58: 3353-3361, 1998.
33. Sachdev D, Hartell JS, Lee AV, Zhang X and Yee D: A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279: 5017-5024, 2004.
34. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE and Ellis LM: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth and metastasis of colon cancer. Lab Invest 82: 1377-1389, 2002. (Pubitemid 35191541)
35. Wu Y, Yakar S, Zhao L, Hennighausen L and LeRoith D: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62: 1030-1035, 2002.
36. Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE and Ellis LM: Insulin-like growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 241: 748-758, 2005.
37. Bredin CG, Liu Z and Klominek J: Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines. Anticancer Res 23: 4877-4884, 2003.
38. Samani AA, Chevet E, Fallavollita L, Galipeau J and Brodt P: Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 64: 3380-3385, 2004.
39. Zhang D, Bar-Eli M, Meloche S and Brodt P: Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 279: 19683-19690, 2004.
40. Tai Y-T, Podar K, Catley L, Tseng Y-H, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C and Anderson KC: Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of β1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 63: 5850-5858, 2003.
41. Zheng DQ, Woodard AS, Tallini G and Languino LR: Substrate specificity of αvβ3 integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT. J Biol Chem 275: 24565-24574, 2000.
42. Clemmons DR, Horvitz G, Engleman W, Nichols T, Moralez A and Nickols GA: Synthetic alphaVbeta3 antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication. Endocrinology 140: 4616-4621, 1999.
43. Kabir-Salmani M, Shiokawa S, Akimoto Y, Sakai K, Nagamatsu S, Sakai K, Nakamura Y, Lotfi A, Kawakami H and Iwashita M: αvβ3 integrin signalling pathway is involved in insulin-like growth factor I-stimulated human extravillous trophoblast cell migration. Endocrinology 144: 1620-1630, 2003.
44. Sekimoto H, Eipper-Mains J, Pond-Tor S and Boney CM: αvβ3 integrins and Pyk2 mediate IGF-I activation of Src and MAPK in 3T3-L1 cells. Mol Endocrinol 19: 1859-1867, 2005.
45. Maile LA and Clemmons DR: The alphaVbeta3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor. Endocrinology 143: 4259-4264, 2002.
46. Ling Y, Maile LA and Clemmons DR: Tyrosine phosphorylation of the beta3-subunit of the alphaVbeta3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor. Mol Endocrinol 17: 1824-1833, 2003.
47. Ling Y, Maile LA, Badley-Clarke J and Clemmons DR: DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signalling in cultured vascular smooth muscle cells. J Biol Chem 280: 3151-3158, 2005.
48. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J and Price JT: Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with αvβ3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 64: 977-984, 2004.